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Abstract
Background
New evidence shows that high density lipoproteins (HDL) have protective effects beyond
their role in reverse cholesterol transport. Reconstituted HDL (rHDL) offer an attractive
means of clinically exploiting these novel effects including cardioprotection against ische-
mia reperfusion injury (IRI). However, basic rHDL composition is limited to apolipoprotein AI
(apoAI) and phospholipids; addition of bioactive compound may enhance its
beneficial effects.
Objective
The aim of this study was to investigate the role of rHDL in post-ischemic model, and to ana-
lyze the potential impact of sphingosine-1-phosphate (S1P) in rHDL formulations.
Methods and Results
The impact of HDL on IRI was investigated using complementary in vivo, ex vivo and in vitro
IRI models. Acute post-ischemic treatment with native HDL significantly reduced infarct size
and cell death in the ex vivo, isolated heart (Langendorff) model and the in vivomodel
(-48%, p<0.01). Treatment with rHDL of basic formulation (apoAI + phospholipids) had a
non-significant impact on cell death in vitro and on the infarct size ex vivo and in vivo. In con-
trast, rHDL containing S1P had a highly significant, protective influence ex vivo, and in vivo
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(-50%, p<0.01). This impact was comparable with the effects observed with native HDL.
Pro-survival signaling proteins, Akt, STAT3 and ERK1/2 were similarly activated by HDL
and rHDL containing S1P both in vitro (isolated cardiomyocytes) and in vivo.
Conclusion
HDL afford protection against IRI in a clinically relevant model (post-ischemia). rHDL is sig-
nificantly protective if supplemented with S1P. The protective impact of HDL appears to tar-
get directly the cardiomyocyte.
Introduction
Ischemia reperfusion injury (IRI) is a major concern for cardiologists in the treatment of myo-
cardial infarction. Limiting the extent of IRI is of primary importance in preventing subsequent
progression to heart failure. The timing of clinical intervention is crucial and for obvious rea-
son, preconditioning is not feasible. It is therefore important to evaluate the application of effi-
cient treatment at the adequate moment.
For several decades, high density lipoproteins (HDL) have been considered a strong nega-
tive predictor of cardiovascular risk, with an inverse relationship to atherosclerotic disease risk.
This beneficial effect on the cardiovascular system has been attributed primarily to its ability to
facilitate cholesterol excretion [1]. Recent evidence has shown that HDL particles have more
widespread, beneficial actions (antioxidant, anti-inflammatory, anti-apoptotic) on vascular
cells [1]. Direct actions of HDL on the heart have been poorly investigated although experi-
mental data have shown that HDL can influence IRI [2, 3]. These effects have been attributed
to several components of the HDL particle, which is complex and heterogeneous (more than
50 peptides and 100 lipids have been shown to be associated with HDL). Although apolipopro-
tein AI (apoAI) constitutes more than 70% of the total protein content in HDL particles, it ap-
pears too simplistic to attribute to apoAI all the beneficial effects.
The HDL complex is being increasingly considered a therapeutic option, notably in the
form of synthetic (reconstituted) HDL (rHDL) whose composition can be controlled and
which, in basic formulations, contains apoAI and phospholipids. It has already been investigat-
ed in several experimental settings in man, although not against IRI.
In the experimental animal model of IRI, administration of rHDL before ischemia improves
post-ischemic cardiac recovery, while the protective impact was reportedly limited when ad-
ministrated at reperfusion [2, 4, 5]. The rHDL used in these studies only contained apoAI
and phospholipids.
Sphingosine-1-phosphate (S1P) is a lipid active on vascular cells. It has been shown to con-
fer protection against IRI. Interestingly, S1P is a constituent of the HDL particle and the level
of S1P in HDL particle is decreased in patients with coronary artery disease [6, 7]. Studies of
the role of HDL and S1P in protection against IRI in vivo are limited to one report, where HDL
were administered prior to ischemia [3]. It employed native HDL (ie isolated from human plas-
ma) and S1P infused independently of HDL. We hypothesised that the artificial addition of
S1P to the basic rHDL formulation could potentiate its action and improve their
therapeutic impact.
The aim of the present study was to extend our investigations of HDL to more physiologi-
cally relevant models of IRI to (i) investigate its protective effect in a post-ischemic, in vivo
model, (ii) explore the impact of rHDL and determine whether addition of S1P to the basic
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rHDL formulation could improve cardioprotection, (iii) investigate molecular mechanisms,
comparing the simplified in vitro with more physiologically relevant ex vivo and in
vivo models.
Our results underline the efficacy of HDL protection of the heart in a post-ischemic context,
which is the most appropriate timing for clinical intervention against acute coronary disease.
They demonstrate that a minimal composition of rHDL requires S1P to achieve cardioprotec-
tion equivalent to that of native HDL. Our data suggest that the protective effect is primarily
mediated by a direct impact on cardiomyocytes. Finally, we demonstrate activation of similar,
protective signaling pathways in the in vitro and in vivo models of IRI.
Materials and Methods
Animals
All experiments involving animals were approved by the Animal Research Ethics Committee
from the faculty of health sciences of University of Cape Town (UCT) for experiments done at
UCT and by the animal ethical committee of the Geneva University Medical School for experi-
ments done in Geneva. Animals were housed and treated in accordance with the Guide for
Care and Use of laboratory Animals Eighth Edition, published by the US National Institute of
Health Publication. Male C57black6 mice aged 8–14 weeks and neonatal Wistar rats were used
in this study.
HDL isolation
HDL (d = 1.063–1.21 g/mL) were isolated by cumulative flotation ultracentrifugation as previ-
ously described [8] from a plasma pool provided by healthy volunteers (authorized by the eth-
ics committee of the University Hospital, Geneva, authorization n° 07–037), dialyzed against
phosphate buffered saline (PBS) containing ethylenediaminetetraacetic acid (EDTA) (0.1mM)
and stored at 4°C. The volunteers provided informed, written consent in accordance with the
PLOS ONE editorial policy.
HDL particles were also isolated from serum mouse. In short, apoB-containing lipoproteins
were removed from 200μL serum by precipitation with 4g/L Na-phosphotungstate and
50mmol/L MgCl2 (final concentration after being added to the sample). HDL particles were
isolated by ultracentrifugation (TLA-100 rotor, 1000000rpm, 5h, 4°C, Beckman Coulter centri-
fuge). HDL protein concentration was measured by Lowry.
rHDL preparation
ApoAI was isolated from delipidated human HDL [8]. Palmitoyloleophosphatidyl choline
(POPC) was purchased from Sigma-Aldrich GmbH (Buchs, Switzerland) and Santa Cruz (Hei-
delberg, Germany). Two different forms of rHDL were prepared by the cholate dialysis proce-
dure [9], maintaining a POPC/apoAI molar ratio of 100:1: rHDL containing POPC and apoAI
and rHDL with addition of S1P (rHDLB) with a POPC/apoAI/S1P molar ration of 1600/16/1
(Sigma-Aldrich GmbH (Buchs, Switzerland). For preparations containing S1P, aliquots from a
stock solution (1.0 mg/mL in methanol) were dried in glass tubes and the POPC/cholate mix-
ture, and then apoAI were added successively, as prescribed by the cholate dialysis procedure.
All preparations were dialyzed 4 days against Tris 10 mM, pH 8.0, NaCl, 0.15M. The S1P con-
centration in rHDLB was 74.8ng/mg apoAI, slightly higher than S1P contained in native HDL
(59ng/mg apoAI) (see S1 Fig.). The amount of S1P injected corresponds to an estimated final
concentration of 1.2μM.
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S1Pmeasurement in HDL
HDL content of S1P was analyzed by liquid-chromatography/tandem mass spectrometry (LC/
MS—MS) (see S1 Methods for details).
Cell culture
Isolation of neonatal ventricular cardiomyocytes was performed with 1 to 2-day-old Wistar
rats. Cells were isolated by digestion with trypsin-EDTA and collagenase as described previous-
ly in detail [10].
Hypoxia protocol
Before hypoxic exposure, cell medium was replaced by modified Tyrode’s solution (in mM:
NaCl 136.9, KCl 2.68, Na2HPO4
.12H2O 8.1, KH2PO4 1.47, CaCl2 0.9, MgCl2
.6H2O 0.49; pH
7.2). The cardiomyocytes were placed in an anaerobic hypoxia chamber containing 5% CO2
and 95% N2 at 37°C for 5h. For normoxic treatment cells were maintained at 37°C in a culture
incubator with 5% CO2. After treatment, cell survival was evaluated by the colorimetric MTT
assay (3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; Calbiochem; La Jolla,
California, USA).
Perfusion of isolated mouse hearts (Fig. 1A)
Mice were anaesthetized via an intraperitoneal injection of sodium pentobarbital (60mg/kg).
The heart was quickly excised and the aorta cannulated for retrograde perfusion in a Langen-
dorff apparatus. Isolated hearts were subjected to a stabilization period (20min) followed by
global ischemia (35min) then a reperfusion period (45min) as previously described [11]. At the
onset of reperfusion, HDL were perfused for 7min via a side pump adjusted to deliver a speci-
fied concentration of HDL (native HDL, 200μg protein/ml; rHDL, apoAI at 140μg/ml, S1P at
500nM). At the end of reperfusion, the hearts were sliced and stained with triphenyltetrazolium
chloride (TTC) 1%. Infarct size (IS) was evaluated by the analysis of the dead and living cell
areas normalized to the total heart area using computerized planimetry (Planimetry+, Boreal
Software, Norway). A minimum of 4 hearts was used in all groups.
In vivo ischemia reperfusion protocol (Fig. 1B)
In vivo IRI was analyzed after ligation of the left anterior descending (LAD) coronary artery. In
brief, mice were anaesthetized with 4% isoflurane and intubated. Mechanical ventilation was
performed (150μl, 120 breaths/min) using a rodent respirator (model 683; Harvard Appara-
tus). Anaesthesia was maintained with 2% isoflurane delivered in 100% O2 through the ventila-
tor. A thoracotomy was performed and an 8–0 prolene suture was passed under the left
anterior descending (LAD) coronary artery. After 45min ischemia, LAD coronary artery occlu-
sion was released and reperfused for different times. After 24h of reperfusion the mice were re-
anaesthetized with ketamine—xylazine (120mg/kg and 16mg/kg, respectively) and the LAD
coronary artery was re-occluded. Evan’s blue dye 2% (Sigma) was injected to delineate the in
vivo area at risk (AAR). The heart were sliced into 5–6 sections and stained with TTC 1% to
allow quantification of infarct size. The different zones were determined using a computerized
planimetric technique (MetaMorph v6.0, Universal Imaging Corporation) and infarct size was
expressed in percentage of AAR (I/AAR). HDL were injected intravenously (retro-orbital) one
minute before reperfusion. For injection, native HDL was used at 100μg protein/g mouse; for
rHDL, apoAI was 80μg/g mouse and S1P was 57ng/g mouse. 80μg of apoAI approximates the
amount of apoAI present in 100μg protein of native HDL.
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Serum cytokine measurement
Sera from PBS, native HDL or rHDLB (rHDL+ S1P) treated mice were collected after 24h re-
perfusion to assess cytokine concentrations. CCL2 and CXCL1 were measured using ELISA
procedures (R&D Systems, Abingdon, UK), according to the manufacturer’s guidelines. The
limit of detection was 15.6pg/ml (CXCL1) and 7.8pg/ml (CCL2). Mean intra- and inter-assay
coefficients of variation (CV) were below 6%.
Histological analysis
Hearts isolated from animals were perfused with NaCl 0.9% to remove blood and frozen in
OCT. They were then cut serially from the occlusion locus to the apex in 7μm sections. In
order to obtain an appropriate and complete sampling of ischemic cardiac regions, five frozen
midventricular cardiac sections (between the coronary ligature and the apex) per animal (eu-
thanized after 24h of reperfusion) distant 630μm from each other were stained and analyzed.
Inflammatory cell recruitment
Mouse heart sections obtained as described above were stained for neutrophils with rat anti-
mouse neutrophil Ly-6B.2 (MCA771G; Serotec) or with anti-mouse neutrophil Ly6G+ (#
551459, BD Pharmingen) antibodies. CD68+ macrophages were stained with rat anti-mouse
CD68 (MCA1957GA; Serotec) antibody. For each heart, the number of cells was counted using
MetaMorph v6.0 (Universal Imaging Corporation) on 5 midventricular cardiac sections per
Fig 1. Experimental protocols. A. Hearts frommice were submitted to the ischemia reperfusion protocol as follows: 20min of stabilization, 35min of no-flow
global ischemia and 45min of reperfusion. After reperfusion, infarct size was determined. Native HDL or rHDL were added for the first 7min of reperfusion. B.
Mice were subjected to LAD occlusion for 45min and hearts were reperfused for different time periods: 5min for Western blot experiments and 24h for infarct
size measurement and histological analysis. Serum frommice reperfused for 24h was collected for analysis of circulating cytokines. Native HDL or rHDL
were injected one min before reperfusion.
doi:10.1371/journal.pone.0119664.g001
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animal, as previously described [12, 13]. Results are expressed as percentages of stained area on
total heart surface area.
Myocardial oxidative stress determination (24h after reperfusion)
Neutrophil, monocyte and eosinophil activation is known to catalyse the formation of hypo-
chlorous acid that reacts with proteins and induces tyrosine halogenation such as 3,5-dibromo-
tyrosine (Di-BrY). Leukocyte-derived oxidative stress was assessed after 24h of reperfusion in
frozen sections of the ischemic hearts by immunostaining for 3,5-dibromotyrosine using a
mouse anti-dibromotyrosine monoclonal antibody (at 10μg/ml, AMS biotechnology, LTD,
Abingdon, UK). To avoid any potential cross-reactivity with mouse heart antigens and to in-
crease the specificity of the primary antibodies, the VECTORM.O.M immunodetection kit
and the VECTOR VIP substrate kit for peroxidase (Vector Laboratories, Inc. Burlingame, CA)
were used, following the manufacturer’s instructions.
Western blot analysis
For protein analysis of in vivo treated mice, hearts were removed after 5min reperfusion, snap-
frozen in liquid nitrogen then stored at −80°C until protein extraction was performed.
Total proteins were extracted from the whole heart by homogenization of the tissue in lysis
buffer containing Tris-HCl (50mM, pH 7.4), NaCl (150mM), glycerol (10%v/v), EDTA
(2mM), EGTA (2mM), Triton X-100 (1%v/v), b-glycerophosphate (40mM), NaF (50mM) and
a mixture of protease inhibitors (Roche, Mannheim, Germany) and phenyl-methyl-sulfonyl
fluoride (1mM). Cardiomyocytes from in vitro studies were treated 5min with HDL (200μg/
ml) or rHDL (apoAI: 160μg/ml). At the end of the treatment cells were washed with PBS and
lysed with lysis buffer. Phosphorylated Akt (Phospho-Akt, serine 473, rabbit polyclonal, cat n°
9271, Cell Signaling), extracellular regulated-signal kinase 1/2 (ERK1/2) (Phospho-ERK1/2,
rabbit polyclonal, cat n° 9101, Cell Signaling), Signal Transducer and Activator of Transcrip-
tion 3 (STAT3) (Phospho-STAT-3 serine727: STAT3-S727 cat n° 9134 and phospho-STAT3
tyrosine 705: STAT3-Y705, cat n° 9131, both rabbit polyclonal from Cell Signaling), were ana-
lyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS—PAGE). Levels of
phosphorylated proteins were normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH, mouse monoclonal antibody cat n° MAB374 fromMillipore, Billerica, MA, USA).
For respective total kinase protein expression the membranes were stripped and reprobed with
total STAT3 anti-rabbit, n° cat 06–596 Millipore), total ERK (rabbit polyclonal, n° cat sc-94,
Santa Cruz Biotechnology, Dallas, TX, USA) and total Akt (rabbit polyclonal, cat n° 9272, Cell
Signaling). Relative densities were determined and quantified with the Odyssey Imager (Li-Cor
Biosciences).
Statistical analysis
All statistical analyses were performed using the software GraphPad Prism 6. Data are express-
ed as mean ± the standard error of the mean (SEM). Comparisons were performed by unpaired
or paired Student t-test (two tail) as well as one-way ANOVA combined with Tukey’s multiple
comparisons post-hoc test where appropriate. p<0.05 was considered significantly different.
Results
rHDL containing S1P induce cardioprotection in a hypoxia model
Our previous in vitro studies on the protective effects of HDL employed rat cardiomyocytes
subjected to pathophysiological insult by doxorubicin. To furnish in vitro data on ischemia
Improving rHDL Composition Enhances Cardioprotection
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more relevant to our ex vivo and in vivo models, we re-examined the effects of native HDL and
rHDL on cardiomyocytes under conditions of hypoxia. As shown in Fig. 2, hypoxia induced a
significant level of cell death (30%, p<0.05). While basic rHDL (POPC+apoAI) did not signifi-
cantly improve cell survival after hypoxia, native HDL and addition of S1P to the basic rHDL
formulation (rHDL+S1P = rHDLB) reduced cell death by 47%±11 and 41% ±19, respectively
(p<0.05).
rHDL containing S1P induce cardioprotection ex vivo and in vivo
Analysis of the impact of rHDL on IRI in the isolated heart allowed us to eliminate potentially
confounding, systemic, anti-inflammatory effects of HDL (for protocol details see Fig. 1A). Na-
tive HDL was used as a positive control. As shown in Fig. 3, native HDL reduced infarct size by
31.7%±3.9 (p<0.001). With respect to rHDL, treatment with basic rHDL (POPC+apoAI) did
not significantly reduce infarct size (p = 0.056). Corresponding to the results observed in vitro,
addition of S1P to basic rHDL resulted in a highly significant reduction in infarct size (Fig. 3;
p<0.001), similar to that observed for native HDL.
To assess the physiological relevance of our treatment protocol, the impact of HDL was ex-
amined in the in vivo model (for details see Fig. 1B). No significant difference between groups
was observed with respect to the myocardial AAR (Fig. 4A). A single injection of native HDL
immediately prior to reperfusion was sufficient to reduce this infarct size by 47.5%±6.8
Fig 2. rHDL containing S1P protect against hypoxia in vitro. Cardiomyocytes were incubated in Tyrode solution, submitted to 5h hypoxia and treated
during hypoxia with native HDL (nHDL), rHDL (apoAI+POPC) or rHDLB (apoAI + POPC + S1P). Cell survival was determined using the MTT assay. Cell
survival is expressed in percentage of normoxia (mean±SEM). *p< 0.05 vs hypoxia, using paired-student t-test, n = 6.
doi:10.1371/journal.pone.0119664.g002
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(p<0.01) (Fig. 4B, 4C). Injection of the phospholipids (POPC) vector alone and basic rHDL
(POPC+apoAI) (p = 0.52 and p = 0.053, respectively) did not have a significant impact on the
infarct size (Fig. 4B, C). By contrast, addition of S1P to basic rHDL (rHDLB) significantly re-
duced infarct size to a degree equivalent to that obtained with native HDL (-49.2%±12.8,
p<0.01; Fig. 4B, C).
The content of human apoAI in serum was measured after reperfusion. Human apoAI was
still present in mouse serum 24h after reperfusion (see S2 Fig. and S3 Fig.). The content of S1P
in HDL particles isolated from mouse serum was not significantly different between groups
after 24h of reperfusion (see S4 Fig. and S5 Fig.).
HDL do not modulate systemic inflammation
HDL are known to modulate the inflammatory response. We investigated this possibility with
the in vivomodel. These experiments were limited to the most protective treatments: native
HDL and rHDLB. We could not find evidence of a reduction in circulating levels of chemokines
CCL2 or CXCL1 by treatment with native HDL or rHDLB, compared to controls (Table 1).
Therefore, we extended our investigations to the inflammatory process within the cardiac tissue.
As shown in Fig. 5, after 24h reperfusion neither native HDL nor rHDLB modulated neutrophil
(Fig. 5A-5D) or macrophage (Fig. 5E, 5F) infiltration of the myocardial tissue compared to con-
trols. Similarly, HDL treatment did not decrease myeloperoxidase-induced protein oxidation as
measured using Di-BrY as a marker (Fig. 6A-6C). Moreover, histological analysis demonstrated
that HDL treatment did not modulate myocardial lipid peroxidation (measured by 4-hydroxy-
Fig 3. rHDL containing S1P protect against ischemia reperfusion injury ex vivo. Isolated hearts were submitted to global ischemia (35min) followed by
reperfusion (45min). At the onset of reperfusion, hearts were treated or not (control) with native HDL (nHDL), rHDL (apoAI+POPC) or rHDLB (apoAI + POPC
+ S1P) during the first 7min. Infarct size is expressed as percentage of total heart area, (mean±SEM). ***p<0.001 vs control using one-way ANOVA
combined with Tukey multiple comparisons post-hoc test, n4.
doi:10.1371/journal.pone.0119664.g003
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2-nonenal (4-HNE) staining) and superoxide (measured by dihydroethidium (DHE) staining)
24h after reperfusion (see S6 Fig.). Thus, one single injection of HDL at reperfusion did not sig-
nificantly reduce the inflammatory response induced by ischemia.
HDL activate comparable intracellular signaling pathways in vivo and in
vitro
We analyzed survival pathways that were previous identified by our in vitro studies based on
doxorubicin treatment of cardiomyocytes. The in vitromodel revealed activation of Akt,
ERK1/2 and STAT3 by native and rHDLB (Fig. 7A). Although basic rHDL induced the phos-
phorylation of these target proteins in cultured cardiomyocytes, treatment with HDL contain-
ing both apoAI and S1P (native HDL or rHDLB) enhanced these actions. These results were
confirmed in vivo where Akt and ERK1/2 were activated by both native HDL and rHDLB
(Fig. 7B). STAT3 was also phosphorylated, although it was more marked with rHDLB than
with native HDL (Fig. 7B).
Discussion
The study demonstrates that post-ischemic treatment with HDL, at the time of reperfusion,
can strongly reduce the extent of myocardial IRI. Moreover, synthetic HDL is an appropriate
Fig 4. Post-ischemic treatment with HDL protects against ischemia reperfusion injury in vivo.Mice were submitted to LAD occlusion for 45min and
hearts were reperfused for 24h. Mice were injected or not (control mice IR) with native HDL (nHDL), POPC, rHDL (apoA1+POPC) or rHDLB (apoAI + POPC
+ S1P) one minute before reperfusion. A.Quantification of area at risk (AAR) per ventricle surface. Data are mean±SEM (n = 9–16 per group). B.
Quantification of infarct size (IS) expressed in % of AAR. Data are mean±SEM (n = 9–16 per group), **p<0.01, vs IR, using one-way ANOVA combined with
Tukey multiple comparisons post-hoc test. C. Representative images of TTC stained middle heart sections of control or treated mice.
doi:10.1371/journal.pone.0119664.g004
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Table 1. Circulating chemokines measured 24h after reperfusion.
chemokines control nHDL p value vs control rHDLB p value vs control
CCL2 (pg/ml) 66.3 [46.1–229.1] 108.4 [57.5–223.7] p = 0.3884 105.3 [38.4–125.8] p = 0.776
CXCl1 (pg/ml) 412.0 [215.0–806.8] 395.2 [329.8–786.5] p = 0.864 558.5 [281.9–840.0] p = 0.607
Data are expressed as median (interquartile range [IQR]) of CCL2 or CXCL1 concentration (pg/ml). n = 7–9.
doi:10.1371/journal.pone.0119664.t001
Fig 5. Post-ischemic treatment with HDL does not decrease leukocyte infiltration.Mice were submitted to LAD occlusion for 45min and hearts were
reperfused for 24h. Mice were injected or not (control mice IR) with native HDL (nHDL), rHDLB (apoAI + POPC + S1P) one minute before reperfusion. A.
Quantification of infiltrated neutrophils (Ly-6B.2+ cells) per area in frozen sections of infarcted hearts at 24h of reperfusion. B. Representative images of
neutrophil (Ly-6B.2+ cells) infiltration. C.Quantification of infiltrated neutrophils (Ly6G+ cells) per area in frozen sections of infarcted hearts at 24h of
reperfusion. D. Representative images of neutrophil (Ly6G+ cell) infiltration. E.Quantification of infiltrated macrophages (CD68+ cells) per area in frozen
sections of infarcted hearts at 24h of reperfusion. F. Representative images of macrophage (CD68+ cells) infiltration. Data are expressed as scattered plots
(mean±SEM, n = 7–10 per group). Results are expressed as percentages of stained area on total heart surface area. No significance difference between
groups was found using unpaired-student t-test.
doi:10.1371/journal.pone.0119664.g005
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substitute for native HDL, when S1P is added as it improves their protective capacity. Both na-
tive and synthetic HDL modulate the same cardiomyocyte signaling pathways, suggesting that
they mediate cardioprotection by similar mechanisms. It implies that a direct action of HDL
on cardiac cells is sufficient to limit IRI, irrespective of any impact on inflammatory factors.
The recent disappointing results of clinical trials that used HDL-cholesterol raising drugs to
reduce vascular risk [14] have re-opened the debate about how to exploit the protective influ-
ence apparently mediated by HDL. One avenue, the use of rHDL as a therapeutic complex in
man, is attracting attention. In experimental settings, administration of rHDL to patients was
associated with improvements in plaque size, endothelial function and anti-inflammatory
markers [15–19] as well as in glucose control and insulin secretion in diabetic patients [20]. In
patients with acute coronary syndrome the use of rHDL leads to an improvement in the blood
lipid profile [21]. Such studies have not investigated IRI and all have employed the basic
rHDL formulation.
Fig 6. Post-ischemic treatment with HDL does not decrease oxidation.Mice were submitted to LAD occlusion for 45min and hearts were reperfused for
24h. Mice were injected or not (control mice IR) with native HDL (nHDL), reHDLB (apoAI + POPC + S1P) one minute before reperfusion. A.Quantification of
Di-BrY content of frozen sections of infarcted hearts after 24h of reperfusion. B. Representative images of Di-BrY stained middle heart sections.C.
Correlation between neutrophil content and Di-BrY staining after 24h of reperfusion in the same hearts.
doi:10.1371/journal.pone.0119664.g006
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Our observations suggest that the therapeutic use of HDL could be extended to IRI in a clin-
ically relevant acute setting. A limited number of older studies in animal models reported that
rHDL could limit ischemic damage to the myocardium [2, 4]. These were, however, largely
based on perfusion with rHDL prior to ischemia, which does not correspond to the real-life,
clinical situation, and concerned essentially the ex vivo, whole heart model. Although treatment
with rHDL at reperfusion has been showed to improve myocardial post-ischemic parameters,
the improvement was reportedly much lesser extent than when rHDL were given before ische-
mia. Of note these studies did not evaluate the consequence of the treatment on the infarct size
[2, 22].
Only two studies have reported on post-ischemic treatment with in vivo models. Kiya et al.
[23] reported that rHDL limited left ventricular remodeling in a rat model. They employed,
however, an experimental model with permanent ligation of a coronary artery and weekly
HDL injections over 4 weeks. This model is clinically inapplicable for acute myocardial infarc-
tion. The second study in a rabbit model reported a beneficial effect on IRI of a synthetic HDL
preparation infused for 60min, starting 5min before reperfusion [2, 5]. Our studies evaluated
acute (only one injection) treatment with rHDL at reperfusion, which may explain some dis-
crepancies. Nevertheless, our data extend the observations from these previous studies with re-
spect of the improvement of the protective capacity of rHDL by addition of S1P that to our
knowledge has never been investigated in vivo.
Although S1P receptor knockout models have provided powerful evidence for the impor-
tance of S1P in HDL-mediated cardioprotection, the role of the lipid is still debated. Our obser-
vations are interesting in this context. Results obtained in our experimental model showed that
although rHDL of basic formulation had a positive effect, they were unable to significantly pro-
tect against IRI. Addition of S1P was necessary to reduce IRI in a significant manner. Interest-
ingly, very recent data have shown that rHDL is a strong acceptor of S1P from erythrocytes
[24]. The ability of HDL to acquire S1P from serum could explain the positive, albeit non-
significant, impact of rHDL observed in vivo. Thus maximal clinical efficiency of rHDL would
appear to require the presence of S1P. The data are consistent with S1P being the component
Fig 7. Activation of intracellular signaling pathways in vitro and in vivo. A.Western blot analysis was performed with proteins extracted from neonatal
cardiomyocytes treated with nHDL, rHDL (apoAI + POPC) or rHDLB (apoAI + POPC+ S1P) for 5min (n = 7–11). Specific bands corresponding to
phosphorylated Akt, ERK1/2 and STAT3 were quantified by densitometry, normalized using GAPDH expression and given as a percentage of the control.B.
Western blot analysis of proteins extracted from hearts submitted to 45min of LAD occlusion followed by 5min of reperfusion. Native HDL (nHDL) or rHDLB
were injected one minute before the reperfusion (n = 9). Data are mean±SEM. *p<0.05, **p<0.01, ***p<0.001 vs control, using unpaired-student t-test.
doi:10.1371/journal.pone.0119664.g007
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of HDL that allows the latter to limit IRI [25]. Observations on the activation of signaling path-
ways concur with this conclusion. Indeed, both native and rHDL containing S1P (rHDLB)
strongly activated ERK1/2, STAT3 and Akt, whereas basic rHDL was significantly less effective.
In our preceding doxorubicin-based studies, we demonstrated the importance of S1P and the
S1P2 receptor for activating ERK1/2 and STAT3 during HDL-mediated cardiomyocyte surviv-
al [26]. Our more recent studies further underline the role of STAT3 in HDL and S1P-induced
cardioprotection [27, 28].
A previous study by Theilmeier et al. [3] attributed a major part of HDL protection to a ni-
tric oxide dependent mechanism involving endothelial cells and observed reduced neutrophil
and macrophage infiltration of cardiac tissue. In our study we could not find evidence of a
modulated inflammatory response, or reduced leukocyte infiltration in the myocardium 24h
after reperfusion. Although only one time point has been investigated, this is consistent with
data from our 3 models (in vitro, ex vivo and in vivo), which indicate that a direct impact of
HDL on the cardiomyocyte is sufficient to mediate cardioprotection.
In conclusion, the present study demonstrates that HDL afford strong protection against
IRI when employed post-ischemia, where synthetic HDL can replicate the effects of native
HDL if S1P is included in the formulation. A direct impact on the cardiac cell is suggested by
our observations of 3 complementary models, with the same survival pathways being activated.
The study supports the potential clinical use of rHDL for protecting against IRI, and underlines
the importance of defining rHDL composition to achieve optimal efficacy of reperfusion strate-
gies. The therapeutic use of rHDL in acute myocardial infarction merits further consideration.
Supporting Information
S1 Methods. This is the Supplementary Material and Methods.
(DOCX)
S1 Fig. S1P content measured in nHDL and rHDLB. The content of S1P in native and artifi-
cial rHDL was also evaluated and adjusted to apoAI content.
(TIF)
S2 Fig. Concentration of human apoAI frommouse serum.Human apoAI in serum from
control or HDL-, rHDL, rHDLB-injected mice (24h after reperfusion) was measured by turbi-
nometry assay. p<0.05 vs control mice, using one-way ANOVA combined with Tukey multi-
ple comparisons post-hoc test (n = 4/group).
(TIF)
S3 Fig. Representative Western blot of human apoAI in mouse serum. Circulating human
apoAI was estimated in serum from non-treated (control IR) or nHDL-, rHDL-, rHDLB-in-
jected mice 24h after reperfusion. Each line represents serum from individual mouse.
(TIF)
S4 Fig. S1P content in HDL isolated from mouse serum.HDL from control or nHDL, rHDL,
rHDLB-injected mouse serum was isolated by ultracentrifugation (n = 3–4). The concentration
of S1P in HDL particle was analyzed by LC/MS—MS.
(TIF)
S5 Fig. Representative SDS-PAGE of HDL isolated from mouse serum.HDL isolated from
control or HDL-, rHDL, rHDLB-injected mice serum (1μl) were run in SDS-PAGE (acrylam-
ide 12%). Total proteins were visualized using Commassie staining. This gel demonstrates the
purity of HDL which content in S1P was analyzed by LC/MS—MS.
(TIF)
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S6 Fig. Post-ischemic treatment with HDL does not decrease oxidation.Mice were submit-
ted to LAD occlusion for 45min and hearts were reperfused for 24h. Mice were injected or not
(control mice IR) with native HDL (nHDL), rHDLB (apoAI + POPC + S1P) one minute before
reperfusion. 4-HNE (A) and DHE (B) content of frozen sections of infarcted hearts at 24 h of
reperfusion. Data are mean±SEM (n = 7–9 per group). B. Representative images of 4-HNE (C)
and DHE (D) stained middle heart sections of vehicle, native HDL or rHDLB-treated mice at
24 h of reperfusion. No significance difference between groups was found using unpaired-stu-
dent t-test.
(TIF)
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